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Abstract
Background: Short cycle treatment interruption could reduce toxicity and drug costs and contribute to further expansion of
antiretroviral therapy (ART) programs.
Methods: A 72 week, non-inferiority trial enrolled one hundred forty six HIV positive persons receiving ART (CD4+ cell count
$125 cells/mm
3 and HIV RNA plasma levels ,50 copies/ml) in one of three arms: continuous, 7 days on/7 days off and 5
days on/2 days off treatment. Primary endpoint was ART treatment failure determined by plasma HIV RNA level, CD4+ cell
count decrease, death attributed to study participation, or opportunistic infection.
Results: Following enrollment of 32 participants, the 7 days on/7 days off arm was closed because of a failure rate of 31%.
Six of 52 (11.5%) participants in the 5 days on/2 days off arm failed. Five had virologic failure and one participant had
immunologic failure. Eleven of 51 (21.6%) participants in the continuous treatment arm failed. Nine had virologic failure with
1 death (lactic acidosis) and 1 clinical failure (extra-pulmonary TB). The upper 97.5% confidence boundary for the difference
between the percent of non-failures in the 5 days on/2 days off arm (88.5% non-failure) compared to continuous treatment
(78.4% non failure) was 4.8% which is well within the preset non-inferiority margin of 15%. No significant difference was
found in time to failure in the 2 study arms (p=0.39).
Conclusions: Short cycle 5 days on/2 days off intermittent ART was at least as effective as continuous therapy.
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Citation: Reynolds SJ, Kityo C, Hallahan CW, Kabuye G, Atwiine D, et al. (2010) A Randomized, Controlled, Trial of Short Cycle Intermittent Compared to
Continuous Antiretroviral Therapy for the Treatment of HIV Infection in Uganda. PLoS ONE 5(4): e10307. doi:10.1371/journal.pone.0010307
Editor: Sean Emery, University of New South Wales, Australia
Received October 19, 2009; Accepted March 22, 2010; Published April 22, 2010
This is an open-access article distributed under the terms of the Creative Commons Public Domain declaration which stipulates that, once placed in the public
domain, this work may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose.
Funding: The study was funded through the Laboratory of Immunoregulation, Division of Intramural Research, National Institute of Allergy and Infectious
Diseases, National Institutes of Health. SJR, CWH, MD, RTD, ASF, TCQ & MAD were employees of the NIH during the study design and implementation period and
were involved in study design, conduct and publication.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: sjr@jhmi.edu
Introduction
Combination antiretroviral therapy (ART) has significantly
decreased morbidity and mortality for HIV-infected persons who
have access to such therapy.[1–3] However, it is now clear that
currently available medications will not eradicate or ‘‘cure’’ HIV
diseasemaking lifelongtherapya necessity.Althoughtherehavebeen
advances in treatment options that have reduced pill burden and
frequency of dosing, the need for daily dosing poses challenges for
long term adherence. While newer formulations of antiretroviral
drugs (ARVs) have reduced certain toxicities, other significant
complications remain and continued exposure has revealed new
toxicities.[4,5] Long termtoxicities can affect adherenceas wellas the
effectiveness of treatment.[6] Several significant international and
domestic initiatives have greatly expanded ART in resource limited
settings. Further reductions in the cost of ARVs could increase the
reach of such programs. Recently, guidance has shifted to earlier
i n i t i a t i o no fA R Ta n dA R Th a sb e e ns u g g e s t e da sap r e v e n t i o n
strategy.[7,8] ART approaches that reduce cost and toxicity while
potentially increasing adherence could significantly enhance the
feasibility of the implementation of such strategies on a large scale.
Researchers have previously evaluated several approaches of
structured treatment interruptions to enhance adherence and
reduce toxicity and cost.[9–11] It is now clear that long cycle
interruptions of ART that allow a rebound of plasma HIV RNA
are not clinically beneficial. The SMART and TRIVICAN trials
showed significant increases in death and opportunistic infections
with long cycles of treatment interruptions, consistent with
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such strategies.[12–14] In sharp contrast, short cycle interruptions
are designed specifically to maintain suppression of plasma HIV
RNA below the limit of assay detection. In pilot studies conducted
in the United States of short cycle interruptions designed to
maintain suppression of plasma HIV RNA below the limit of
detection, we observed that 7 days on and 7 days off ARV
maintained suppression of plasma HIV RNA below the limit of
detection and reduced certain laboratory markers of toxicity with
certain regimens.[10,15] However, strict adherence to the 7 day
cycles was essential for the success of such an approach. Because of
the potential difficulty for certain individuals to maintain strict
adherence to such cycles, we reasoned that more ‘‘user-friendly’’
short cycle ARV interruption approaches could have greater
implementation feasibility and clinical relevance. Based on these
findings, we initiated a randomized, controlled, non-inferiority
trial of two short cycle intermittent ART regimens (7 days on and
7 days off and 5 days on and 2 days off) compared to continuous
ART. Because of the potential applicability of those strategies to
resource limited settings, the study was conducted in Uganda. The
5 days on 2 days off regimen was based on the known kinetics of
the rebound of plasma HIV RNA following a discontinuation of
ART and the potential clinical applicability of a regimen that
allowed treatment interruptions on weekends which could allow
for novel approaches such as directly observed therapy (DOT) in
certain settings such as schools and the workplace and could be
useful in expanding the use of ART earlier in the course of
disease.[16]
We here report an evaluation of a randomized, controlled, non-
inferiority trial of two regimens of short cycle intermittent
compared to continuous ART on virologic, immunologic, toxicity
and adherence parameters.
Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.
Participants
Ethics Statement: The study protocol was reviewed and
approved by the Uganda National Council for Science and
Technology (UNCST), and by the Institutional Review Boards
(IRBs) of the National AIDS Research Committee of the UNCST,
Uganda and the National Institute of Allergy and Infectious
Diseases, National Institutes of Health (NIAID/NIH).
HIV-infected persons receiving ART at the Joint Clinical
Research Center (JCRC) in Kampala, Uganda, with a CD4+ cell
count equal to or greater than 125 cells/mm
3 of whole blood and
plasma HIV RNA below 50 copies per milliliter of plasma were
eligible following signed informed consent. A confirmatory HIV
test was required prior to enrollment. Participants were required to
be receiving at least 3 ARVs including a protease inhibitor or the
non-nucleoside reverse transcriptase inhibitor, efavirenz. Patients
receiving a nevirapine-based regime were required to switch to a
protease inhibitor or efavirenz if they were randomized to the
interrupted arm. Nine patients in the 5 days on/2 days off arm and
7 participants in the 7 days on/7 days off arm were on nevirapine
and switched to efavirenz for study enrollment. Stavudine was
dosed by weight, participants weighing .60 kg received 40 mg,
those weighing ,60 kg received 30 mg. All participants paid for
their ARVs, consistent with standard practice at the JCRC. It
should be noted that at the time the study was initiated, large
international programs to support the cost of ART had not begun.
Such programming was not available until a large number of
patients had already been enrolled. It was the decision of the
investigators and the review boards that changing the payment
practices mid-study could bias the results. Trial oversight was
provided by and independent Data Safety and Monitoring Board
(DSMB). Clinicaltrials.gov registry number NCT00339456.
Study design
The study was designed to test non-inferiority of two short
cycle intermittent ART regimens (7 days on/7 days off and 5
days on/2 days off) compared to continuous ART with 57
patients (52 plus 5 allowed for attrition) randomized in a 1-1-1
manner to each arm and followed for 72 weeks (73 weeks for the
interrupted arms because all lab tests were done during on-
treatment periods). The primary endpoint was ART treatment
failure determined by a plasma HIV RNA level equal to or
greater than 10,000 copies on any one evaluation, a plasma HIV
RNA level equal to or greater than 1,000 copies on two
consecutive measurements, a plasma HIV RNA level greater
than 400 copies/ml at the end of the study, a CD4+ cell count
decrease of greater than 30 percent from baseline on 2
consecutive measurements, death attributed to study participa-
tion or occurrence of an opportunistic infection. The primary
endpoint was changed during the study by the protocol team
from ,50 copies/ml to ,400 copies/ml (end of study) to
eliminate the inclusion of low-level viral blips. Patients who
experienced treatment failure received standard clinical care in
Uganda including switching of ARV regimen, where appropriate.
They were followed until 30 days after their plasma viremia and/
or CD4+ cell count returned to baseline if they changed therapy
or for 30 days from the time of treatment failure if they decided
not to change therapy. Laboratory safety monitoring and HIV
viral load measurements (Amplicor HIV-1 Monitor v1.5 –
Roche, Switzerland ) were performed on site at the JCRC.
HIV genotyping (Trugene HIV-1 Genotyping Kit, Visible
Genetics – Siemens Healthcare Diagnostics, Inc., Tarrytown,
NY) was performed off-site at SAIC-Frederick, Inc., Frederick,
Maryland.
Data collection and follow-up
Participants were evaluated for standard clinical, virologic,
immunologic, and adherence parameters at weeks 2 and 4
following enrollment (interrupted arms only, not included in
outcome analysis) and every 6 weeks thereafter including toxicity
monitoring (renal toxicity, ALT and AST were evaluated every 12
weeks and lipid profiles were done every 6 months). Lipodystropy,
peripheral neuropathy and lactic acidosis were determined by the
treating physician’s assessment, clinical symptoms and laboratory
confirmation (serum lactate). All laboratory evaluations were
provided to the participants free of charge. Intervening visits were
scheduled based on clinical standard of care or relevant failure
parameters. All evaluations except the end of study evaluation
were performed at the end of the off drug period in the
intermittent arm. Adherence to ART was measured using patient
maintained study calendars which were recorded at all study visits,
adherence rates based on self-reported diaries were then calculated
based on the percentage of drugs taken.
Interim monitoring of safety and efficacy
An independent data and safety monitoring board (DSMB)
reviewed all safety data and treatment failures on a bi-annual basis
and at least yearly after 50% of participants were enrolled in each
treatment arm.
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A sample size of 57 individuals in each treatment group (52 plus
5 allowed for attrition) was determined for a 95% non-failure rate
in each study group with a non-inferiority margin of 15%, an
alpha (type I error) of 0.025 and 81% power using the Farrington
and Manning method.[17] The non-inferiority of the 5 days on/2
days off ART arm to continuous ART arm was assessed by
constructing the upper limit of a 97.5% confidence interval for the
difference in proportions, continuous ART minus 5 days on/2
days off, of those successfully completing the study.[18]
Paired differences and the median correlations, determined by
the Spearman rank method, were tested for significance by the
Wilcoxon sign rank test. The Wilcoxon two-sample test was used
to compare independent groups, and Fisher’s exact test was used
to compare frequencies of categorical variables. Comparison of
Kaplan-Meier survival curves was done by the log-rank test. The
significance of the ratios of rates of occurrences of adverse events
was determined by the exact rate ratio test based on the Poisson
distribution. Exact methods were used so that p values and
confidence intervals are properly defined even when the counts are
very small or zero.[19] The calculations were done using the
‘rateratio test’ R package. [20] Adjustment of p values for multiple
testing was performed by the Bonferroni method.
Role of the funding source
The study was funded through the Division of Intramural
Research, NIAID/NIH. SJR, CWH, MD, RTD, ASF, TCQ &




A total of 146 HIV-positive participants were enrolled in the
trial between 2002 and 2005: 32 in the 7 days on/7 days off arm,
57 in the 5 days on/2 days off arm and 57 in the continuous arm.
Five individuals in the 5 days on 2 days off group left the study (2
lost-to-follow-up, 1 relocated, 1 reverted to continuous ART and 1
with renal failure died). Five in the continuous arm were lost-to-
follow-up resulting in 52 with data in the interrupted and 51 in the
continuous arm at week 72/73 (Figure 1). Fifty-six participants in
the continuous arm (one withdrew without participating and was
excluded from analysis) and 57 participants in the 5 days on/2
days off ART are included in the intent-to-treat analysis. Table 1
summarizes the key baseline characteristics of the participants.
The groups were similar in all characteristics upon study entry.
Primary endpoint
Following the enrollment of 32 participants in the 7 days on and
7 days off arm, the DSMB agreed with the principal investigator to
terminate that arm because of a failure rate of 31% found during
the interim analysis in the fall of 2004 (3 participants had
withdrawn and 9/29 remaining participants had failed).
Six of 52 (11.5%) participants who completed the 5 days on/2
days off arm failed. Five of these participants had virologic failure
all with a viral load greater than 10,000 copies/ml (median
VL=50,130 copies/ml; interquartile range (IQR) 14,398 to
50,551 and one participant had immunologic failure. In
comparison, eleven of 51 (21.6%) participants who completed
the continuous treatment arm failed. Nine of these participants
had virologic failure. Six failed with a viral load greater than
10,000 copies/ml, one with a viral load greater than 1,000 and 2
with a viral load greater than 400 at week 72(median
VL=24,410 copies/ml; IQR: 4,394 to 86,316 copies/ml) The
remaining 2 failures included 1 death (lactic acidosis) and 1 clinical
failure (extra-pulmonary TB). The upper 97.5% confidence
boundary for the difference between the percent of non-failures
in the 5 days on/2 days off (88.5% non-failure) arm compared to
continuous treatment (78.4% non failure) was 4.8% which is well
within the preset non-inferiority margin of 15%. In the modified
intent-to-treat analysis which designated the 5 in each group who
discontinued treatment as failures, the upper 97.5% confidence
boundary for the difference between the percent of non-failures in
the 5 days on/2 days off, 80.7% (46 of 57), and that in the
continuously treated, 71.4% (40 of 56) was 6.6% which is within
the preset non-inferiority margin of 15%. In the intent-to-treat
analysis with 57 in each group, the upper 97.5% confidence
boundary for the difference between the 80.7% (46 of 57) non-
failures in the 5 days on/2 days off, and the 70.2% (40 of 57) non-
failures in the continuously treated arm was 5.4% which is again
well within the preset non-inferiority margin of 15%. No
significant difference was found in time to failure in the 2 study
arms, p=0.39 (Figure 2).
Immunologic responses to treatment
As mentioned above, only 1 participant in the 5 days on/2 days
off arm failed by protocol defined immunologic criteria (CD4
decrease of .30% on 2 consecutive measurements) at week 12 of
follow-up. This participant remained virologically suppressed
(,50 copies/ml) through week 73 suggesting that this was not a
true failure but merely a fluctuation in CD4+ T cell count. CD4+ T
cell counts were correlated with weeks on treatment in the
continuous treatment arm (median r=0.54, p,0.001) and in the
5 days on, 2 days off arm (r=0.57, p,0.001). The correlations in
the two groups were not statistically different (p=0.33). For the 46
individualsinthe5dayson/2offarmandthe40inthecontinuously
treated arm who successfully completed the study the median
CD4+ T cell counts at baseline were similar in the two arms (255
and 271/mm
3, respectively, p=0.85), at week 24 (347 and 293/
mm
3, respectively, p=0.30), at week 48 (399 and 318/mm
3,
respectively, p=0.55) and marginally different at week 72/73
(p=0.08)(Figure 3A). The median paired changes in CD4+ T cells
from baseline were not statistically different at week 24 (48 and 15/
mm
3, respectively, p=0.21) nor at week 48 (90 and 69/mm
3,
respectively, p=0.90). The median paired difference in CD4+ T
cells was statistically greater in the 5 days on/2 days off arm at week
72/73 (p=0.01)(Figure 3B) None of the virologic failures
experienced a corresponding immunologic failure during follow-up.
Toxicity
The rates of lactic acidosis, lipodystrophy and peripheral
neuropathy were compared among participants receiving stavudine
within the continuous versus 5 days on/2 days off ART groups. The
data were normalized for comparison between groups by reporting
data as events per 100 person years. Among the 40 participants
receiving continuous stavudine, 5 cases of lactic acidosis as
determined by clinical findings and arterial blood levels of lactate
occurred (resulting in one death), with an incidence of 11.4/100
person years, whereas no occurrences of lactic acidosis occurred
among 44 participants receiving intermittent ART that included
stavudine (p=0.04). A reduction in lipodystrophy was also observed
with 5 cases in the continuous treatment arm (incidence 11.4/100
person-years) compared with 1 case in the intermittent treatment
arm (incidence 1.8/100 person-years) (p=0.13). The rate of
lipodystrophy in the continuous arm was 6.2 times the rate in the
5 days on and 2 days off arm (95% confidence interval {CI}: 0.7,
293). The rates of peripheral neuropathy were similar in both arms
(Table 2) with the occurrence in the continuous arm 1.5 times (95%
Short Cycle Intermittent ART
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were no cases of lactic acidosis in the 5 days on 2 days off arm, the
ratio comparing the continuous and intermittent rates was infinite
with a 95% CI lower limit of 1.13, i.e. greater than 1. Participants
who developed lipodystrophy, peripheral neuropathy or lactic
acidosis were switched from stavudine to zidovudine as standard of
care at the time.
One patient receiving 5 days on and 2 days off ART died from
chronic renal failure that predated enrollment; the event was
determined to be unrelated to the study by investigators in
Uganda. The patient had a plasma HIV RNA level of less than 50
copies per milliliter of plasma at death and a CD4+ T cell count at
baseline and death of 171 and 349, respectively. No other
significant hepatotoxicity, renal toxicity or anemia were observed
during follow up with similar AST, ALT and creatinine
measurements between study arms at 73 weeks (Table 2). Median
LDL cholesterol levels were slightly lower at 73 weeks comparing
continuous versus intermittent treatment arms (96 versus 123,
p=0.08).
Adherence
Overall adherence to ARVs for the study was greater than 95%
in both study arms based on participant diaries. Pharmacy records
were consistent with the high level of reported adherence
measured during the study (data not shown).
Antiretroviral resistance
Clinical monitoring of mutations associated with antiretroviral
drugs resistance was not available in Uganda during the study
period. Consistent with standard clinical care at the JCRC and per
protocol, and with review and monitoring by the DSMB and the
IRB, patients were evaluated for failure by laboratory and clinical
Figure 1. Flow diagram for study eligibility and follow-up.
doi:10.1371/journal.pone.0010307.g001
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including switching of ARV regimen where appropriate. Geno-
typic evaluation of mutations associated with ARV resistance was
performed by SAIC-Frederick, Inc., Frederick, Maryland and the
results were made available to clinicians in Uganda.
Genotyping was performed on 4 out of 5 of the participants in
the 5 days on 2 days off arm at the first viral load measured
.1000 copies/ml. Each participant was receiving an efavirenz-
based regimen that included lamivudine and each had mutations
consistent with resistance to efavirenz and lamivudine (Table 3).
No participant developed thymidine analogue mutations (TAMS)
or evidence of nucleoside analogue resistance apart from one
individual who developed an A62V insertion as previously
reported.[21] Genotyping was also performed on 5 of the 7
participants in the continuous treatment arm who developed
virologic failure during follow-up (first VL.1000 copies/ml). Two
participants had wild type virus, 3 had mutations consistent with
resistance to efavirenz and one had a mutation consistent with
resistance to lamivudine. None of the participants in the
continuous arm had TAMS or nucleoside analogue resistance,
as previously reported.[21]
Discussion
The present study demonstrates that short cycle intermittent
ART defined as 5 days on/2 days off is at least as effective as
continuous ART over a 72/73 week follow-up period. The data
are consistent with the results of a pilot study that was begun in the
United States after this randomized, controlled trial was underway
and with a recent report of significantly increased risk of failure
with interruptions beyond 2 days.[22,23] Our findings are also
consistent with those of the FOTO study which found that
participants on a 5 day on/2 day off interruption strategy receiving
tenofovir, emtricitabine and efavirenz maintained virologic
suppression at 24 weeks.[24] The primary endpoint, ART
treatment failure, was reached by a lower percentage of
participants in the intermittent arm than the continuous treatment
arm by 73 weeks of study follow-up. The early termination of the 7
days on/7 days off arm due to a high failure rate was consistent
with another trial reported after the present study was begun.[25]
It is important to point out that failures that have been reported in
treatment interruption studies have invariably been associated
with a rebound in plasma viremia during the period of intermittent
discontinuation of ARVs.[12,13] Such rebounds are generally
associated with the emergence of drug resistance and the depletion
of CD4+ T cells.[12,26] We chose the 5 days on/2 days off
regimen of treatment interruption to study because previous
experience with the kinetics of plasma rebound following
interruption of ART strongly indicates that plasma viremia that
had been suppressed below the level of detection (,50 copies per
ml) by ART does not generally rebound during the 2 day drug-
interruption period.
Although the trial was not powered to show superiority, it was
interesting that there were nearly twice as many failures in the
continuous arm compared to the 5 days on/2 days off arm (11 and
6, respectively). The adherence data collected indicated high levels
of adherence in each arm. However, 2 of 5 participants with
virologic failure in the continuous arm evaluated for drug
resistance had wild-type virus, suggesting poor adherence. Those
results are compatible with the possibility that scheduled
Figure 2. Kaplan-Meier Survival Curve with Time to Failure. No
difference was found in the time to failure in the 2 groups during the
72/73 week study.
doi:10.1371/journal.pone.0010307.g002
Table 1. Baseline Characteristics.
Baseline Characteristic Continuous n=56 5 Days On/2 Days Off n=57 7 Days On/7 Days Off** n=32
Age (year) 38 (33,44)* 38 (34, 46) 38 (32, 43)
Females 36 (64%) 35 (61%) 21 (66%)
Males 20 (36%) 22 (39%) 11 (34%)
BMI
# 25 (22,29) 25 (23, 29) 25 (22, 29)
CD4 T cells (cells/mm) 262 (192,389) 264 (219, 405) 268 (213, 375)
HIV RNA (copies/ml) ,50 (,50, ,50) ,50 (,50, ,50) ,50 (,50, ,50)
PI based regimen 1 (1.8%) 1 (1.8%) 2 (6.2%)
NNRTI based regimen 55 (98%) 56 (98%) 30 (94%)
Stavudine backbone 40 (71%) 44 (77%) 21 (66%)
Zidovudine backbone 16 (29%) 13 (23%) 11 (34%)
Pre-study ART exposure time (weeks)(IQR) 49 (29–83) 48 (30–69) 46 (33,76)
#n=55 in Continuous arm.
*Median (IQR).
**The 7 days on and 7 days off arm was closed following enrollment of 32 participants because of a 31% failure rate in this group found during interim analysis.
doi:10.1371/journal.pone.0010307.t001
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participants in the 5 days on/2 days off arm developed genetic
mutations consistent with resistance to both lamivudine and
efavirenz while 3 of 5 participants in the continuous arm
developed mutations consistent with resistance to efavirenz and
only 1 developed resistance to lamivudine with a second
participant developing lamivudine resistance at a later follow-up
visit. Our study was not powered to specifically look at differences
in genotypic resistance patterns and also used self-reported
adherence, known to be an imperfect measure, limiting our ability
to draw any firm conclusions from these findings.[27]
There was evidence of reduced toxicities associated with
intermittent ART. This was particularly striking among the subset
of participants receiving stavudine containing ART which is
Figure 3. A. Change in CD4+ T cells for participants successfully completing 72/73 weeks. The CD4+ T cell counts in the continuously
treated (N=40) and in the 5 days on/2 days off (N=46) arms were similar at baseline (255 and 271/mm
3, respectively, p=0.85) and marginally
different at week 72/73 (330 and 429/mm
3, respectively, p=0.08). B. The median paired difference in CD4+ T cells between baseline and week 72/73
was greater in the 5 days on/2 days off group (114/mm
3) than in the continuously treated group (68/mm
3). (p=0.01). The lines across the box
indicates the median values; the boxes contain the 25–75% interquartile range; and the whiskers extend to the highest and lowest values.
doi:10.1371/journal.pone.0010307.g003
Table 2. Toxicity.
Event (cases/100py)* Continuous 5 Days On/2 Days Off p-value
Lactic Acidosis 11.4 0 0.04
Lipodystrophy 11.4 1.8 0.13





Total Cholesterol (mg/dL) 176 (141-194) [38] 192 (174-220) [43] 0.15
LDL Cholesterol (mg/dL) 96 (76-127) [36] 123 (106-139) [43] 0.08
HDL Cholesterol (mg/dL) 42 (35-50) [37] 45 (34-58) [43] 0.99
Triglycerides (mg/dL) 149 (88-212) [36] 144 (98-212) [42] 0.99
AST (IU/L) 21 (16-31) [27] 22 (17-24) [35] 0.99
ALT (IU/L) 20 (14-32) [27] 18 (13-25) [35] 0.99
Creatinine (mg/dL) 0.74 (0.62-0.83) [35] 0.76 (0.68-090) [43] 0.54
*stavudine patient years, subanalysis of participants receiving stavudine containing regimens.
**Cholesterol, liver function tests and creatinine for patients followed 72/73 weeks (all HAART regimens).
doi:10.1371/journal.pone.0010307.t002
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replace it with other nucleoside reverse transcriptase inhibitors.
We observed a marked reduction in the rate of lactic acidosis
among participants receiving intermittent stavudine with no cases
detected in this group compared to 5 cases in the continuous
treatment arm. A similar although not statistically significant
reduction in lipodystrophy was also observed among participants
receiving intermittent stavudine in our study. This finding is
consistent with reports that mitochondrial toxicity associated with
stavudine appears to be at least partially dose dependent.[28] Of
note, lipodystrophy was physician defined which could result in
measurement bias. If larger clinical trials validate reductions in
debilitating and fatal adverse reactions observed in this trial, short
cycle structured treatment interruptions could have particular
relevance for earlier initiation of ART and ART as a viable
prevention strategy.
Immunologic responses to ART were robust in both intermit-
tent and continuous treatment arms. Although there was a
significantly greater increase in CD4+ T cell counts between arms
for patients followed more than 52 weeks, the clinical relevance of
this finding is unclear. Larger trials would be needed to validate
those results and to determine their clinical significance.
Consistent with recent publications from other resource limited
settings, immunologic failure was not observed despite several
episodes of virologic failure.[29–31] Of note, none of the
participants in this study who had developed virologic failure
and genetic mutations associated with ARV resistance would have
been detected by the current WHO guidelines for determining
ARV failure and changing to second line regimens based on
immunologic criteria alone, highlighting the role of virologic
evaluations to determine treatment failure.[32]
The present study has several limitations. It was not powered to
evaluate superiority or long term outcomes including death. The
protocol included only subjects on efavirenz in the intermittent
arms due to the concern of nevirapine resistance. Because
nevirapine is extensively used in low and middle income countries
this might limit the applicability of our findings. The continuous
treatment arm had a higher than expected failure rate than used in
the original statistical design which could impact on the overall
conclusion of non-inferiority. The methodology used to measure
adherence relied on participant diaries which may not reflect the
true adherence levels of the different treatment arms in the study.
Finally, the patient population at the JCRC tended to be of higher
socioeconomic status during the time of the study and thus, most
were able to pay for their ART. A larger trial will be needed to
more fully address short cycle intermittent therapy among patients
representing a wide range of demographies.
Since 5 days on/2 days off intermittent therapy has been shown
to be as least as effective as continuous therapy, this strategy could
have particular importance for programs of directly observed
therapy (DOT) for difficult to treat populations including children
and adolescents attending school 5 days a week. It could also be
relevant for workplace programs. The possibility of decreased
toxicity could be relevant as treatment guidelines shift to initiating
ART earlier in the course of disease. Drug treatment costs could
also be 29 percent lower with a 5 days on/2 days off treatment
regimen. Finally, as guidance shifts to earlier initiation of ART, a
less expensive, ‘‘user-friendly’’ approach with reduced toxicity
could be significant for scale-up of those strategies, particularly in
the developing world.
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Table 3. Reverse Transcriptase Genotypic Resistance Among Participants with Virologic Failure.
Participant Study Arm Failure Week HIV RNA Level (copies/ml) Major RT Mutations
6 5 on/2 off 38 50 130 K103N, M184V
31 5 on/2 off 42 60 899 K103N, M184V
248 5 on/2 off 12 14 398 K101P, K103N
M184V
258 5 on/2 off 60 50 551 K103N, V1081
M184V, P225H
9 Continuous 18 24 400 K103N
21 Continuous 54 205 517 None
81 Continuous 72 4 394 Genotype failed
98 Continuous 24 56 800 K103N, M1841
245 Continuous 18 18 933 None
256 Continuous 54 128 231 K103N
doi:10.1371/journal.pone.0010307.t003
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